‘Ex­cit­ed to be back’: Roche’s se­quel to failed Alzheimer’s an­ti­body looks promis­ing in ear­ly study

A year ago, Roche’s fu­ture in Alzheimer’s dis­ease looked un­cer­tain. At an Alzheimer’s con­fer­ence in San Fran­cis­co, the phar­ma­ceu­ti­cal com­pa­ny an­nounced that its amy­loid-tar­get­ing an­ti­body …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER